[Federal Register Volume 69, Number 173 (Wednesday, September 8, 2004)]
[Notices]
[Pages 54295-54296]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-20293]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Integrin Alpha-V Beta-3 Antagonists for Use in Imaging and Therapy

    S. Narasimhan Danthi et al. (CC), U.S. Patent Application filed 04 
Aug 2004 (DHHS Reference No. E-170-2004/0-US-01).
    Licensing Contact: Michael Shmilovich; 301/435-5019; 
[email protected].
    Available for licensing are compounds as shown below for imaging 
and therapy. These compounds are integrin [alpha]v[beta]3 receptor 
antagonists and are described and claimed in a patent application 
available for review. The patent application also includes claim 
coverage for the administration of these compounds containing a 
detectable moiety or pharmaceutical compositions of such imaging agents 
as part of the imaging of cells that express integrin [alpha]v[beta]3.

[[Page 54296]]

[GRAPHIC] [TIFF OMITTED] TN08SE04.008

    In which: X is either NH, O, or S; n is zero or a positive integer; 
R1 is either CH2, NH, O, or S; R2 is 
either CHR7, NR7, O, or S, in which R7 
is H or alkyl; R3 and R4, which are either the 
same or different from each other, are either H, alkyl, aryl, 
arylalkyl, cycloalkyl, cycloalkylalkyl, alkyl-substituted aryl, 
(alkylsubstitutedaryl)alkyl, hydroxy-substituted alkyl, hydroxy-
substituted aryl, or (hydroxy-substituted aryl)alkyl; R5 is 
either CH2, NH, O, or S; and R6 is either H or 
C(=Y)-R8-R9, in which: Y is either NH, O, or S; 
R8 is either CHR10, NR10, O, or S, in 
which R10 is H or alkyl; and R9 is either H, 
alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, alkylsubstituted 
aryl, (alkyl-substituted aryl)alkyl, hydroxy-substituted alkyl, 
hydroxy-substituted aryl, or (hydroxy-substituted aryl)alkyl.

Use of Protein Kinase C Delta Inhibitor, Specifically Rottlerin, Alone 
or in Further Combination With Staurosporine, in the Treatment of 
Metastatic Epithelioid Melanoma

    Denise Simmons (NCI), U.S. Provisional Application No. 60/531,876 
filed 22 Dec 2003 (DHHS Reference No. E-311-2003/0-US-01).
    Licensing Contact: Mojdeh Bahar; 301/435-2950; [email protected].
    This invention is directed to the use of a protein kinase C delta 
inhibitor, specifically rottlerin, alone or in further combination with 
staurosporine, in the treatment of metastatic epithelioid melanoma. 
Preliminary studies show that treatment of cells from a metastasized 
human epithelioid melanoma with rottlerin reduced cellular 
proliferation by 90%, without affecting proliferation or morphology of 
normal melanocytes. Cells from the matched primary site tumor of the 
same patient were not affected by this inhibitor, nor were cells from a 
matched tumor pair of fibroblastoid morphology obtained from a second 
patient. Treatment of cells from a metastasized human epithelioid 
melanoma with staurosporine caused an increase in branching and in the 
number of processes in the melanoma cells, without affecting cell 
number. These staurosporine-induced changes may be indicative of 
differentiation.

    Dated: August 27, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 04-20293 Filed 9-7-04; 8:45 am]
BILLING CODE 4140-01-P